Good Life Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.0% during the first quarter, Holdings Channel reports. The fund owned 17,979 shares of the company’s stock after buying an additional 1,176 shares during the period. Johnson & Johnson makes up approximately 1.1% of Good Life Advisors LLC’s holdings, making the stock its 22nd largest position. Good Life Advisors LLC’s holdings in Johnson & Johnson were worth $2,225,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. SNS Financial Group LLC raised its stake in shares of Johnson & Johnson by 39.5% in the first quarter. SNS Financial Group LLC now owns 16,093 shares of the company’s stock valued at $2,004,000 after buying an additional 4,556 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Johnson & Johnson by 359.2% in the first quarter. WINTON GROUP Ltd now owns 210,451 shares of the company’s stock valued at $24,861,000 after buying an additional 164,619 shares during the last quarter. Vontobel Swiss Wealth Advisors AG raised its stake in shares of Johnson & Johnson by 16.5% in the first quarter. Vontobel Swiss Wealth Advisors AG now owns 14,553 shares of the company’s stock valued at $1,813,000 after buying an additional 2,066 shares during the last quarter. Empirical Finance LLC raised its stake in shares of Johnson & Johnson by 55.4% in the first quarter. Empirical Finance LLC now owns 1,936 shares of the company’s stock valued at $241,000 after buying an additional 690 shares during the last quarter. Finally, AE Wealth Management LLC raised its stake in shares of Johnson & Johnson by 74.8% in the first quarter. AE Wealth Management LLC now owns 23,841 shares of the company’s stock valued at $2,969,000 after buying an additional 10,204 shares during the last quarter. Institutional investors own 66.06% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) traded up 0.35% on Wednesday, hitting $132.73. The stock had a trading volume of 741,197 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The company has a market cap of $357.55 billion, a P/E ratio of 22.46 and a beta of 0.78. The stock has a 50 day moving average price of $133.35 and a 200 day moving average price of $125.64.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The business had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.74 EPS. On average, equities research analysts expect that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.

WARNING: “Johnson & Johnson (NYSE:JNJ) Shares Bought by Good Life Advisors LLC” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/09/johnson-johnson-nysejnj-shares-bought-by-good-life-advisors-llc.html.

Several brokerages have issued reports on JNJ. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target on the stock. in a report on Friday, July 21st. Finally, BTIG Research lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target on the stock. in a report on Friday, July 21st. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $133.72.

In other news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.